echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Autophagy: Scientists discover a new strategy to effectively eliminate cancer cells

    Autophagy: Scientists discover a new strategy to effectively eliminate cancer cells

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    JUNE 13, 2020 /PRNewswire/ -- In a recent study published in the international journal Autophagy, scientists from the Autonomous University of Barcelona and others have developed a new strategy against cancer, inducing strong pressure on tumors to promote cancer cell destruction through autophagy; PHOTO SOURCE: THE ANTI-TUMOR DRUG ABTL0812 INDUCES A STRESS RESPONSE IN TUMORS, WHICH CAN PRODUCE CYTOTOXIC AUTOPHAGY, WHICH IN TURN PROMOTES CELL DESTRUCTION, AND THE COMBINATION OF THIS MOLECULE AND STANDARD CHEMOTHERAPY HAS BEEN CONFIRMED IN MALIGNANT ENDOMETRIAL CANCER AND SQUAMOUS LUNG CANCER, ACCORDING TO INC-UAB RESEARCHERSThe new cancer-fighting strategy is based on the manipulation of dihydroceramides, a class of cell lipids, and the researchers found for the first time that two stress-related proteins, CHOPAs (and TRIB3), were tested from blood samples of patients underclinical trials or used as biomarkers to indicate drug efficacyPreviously, researchers analyzed the molecular mechanisms of ABTL0812 to apply antitumor activity, and researcher Jose Miguel Lizcano said that the death of cancer cells or changes in the level of dihydromidein in the cells, the increase in dihydromide levels can cause severe pressure in the endosomes, resulting in the accumulation of defective proteins, and finally the cells activate a compensatory reaction called unfolded protein reaction (UPR, Unfolded ProteinResponse) if the reaction lasts longerThis study also explains why ABTL0812 does not affect non-cancerous cells, the main advantage of this molecule is its specific targeting effect on tumor cells, in order to survive in a harsh environment, cancer cells need to be adapted by increasing the pressure level of the endobox, and this drug can stimulate cancer cells across the pressure level spent on the protective effect, leading to cancer cell death, and health cells do not seem to have an effectThis new mechanism of action could be used to develop new treatments for multiple types of cancer, but in fact, the researchers also provide preliminary findings on models of pancreatic and other bile cancersFinally, the researchers said that the results of this study expanded the use of the new anti-tumor drug ABTL0812 in other cancer modes (in addition to endometrial cancer and squamous lung cancer), and that they will continue to study the use of the drug for many other types of cancer(BioValleyBioon.com) Original origins: Pau Muoz-Guardiola, Josefina Casas, Elisabet Meg?as-Roda, et alThe anti-cancer drug ABTL0812 ter-mediated cytotoxic autotoxicphagy by dihydroceramide levels in cancer, autophagy (2020)DOI: 10.1080/15548627.2020.1761651
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.